HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Related Collections Related Article

J Thorac Cardiovasc Surg 2008;135:1360-1361
© 2008 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Discussion

Dr Cleveland (Denver, Colo). Jim, I congratulate you and your coauthors at the Utah artificial heart program for achieving exemplary outcomes with a complex and challenging group of patients undergoing LVAD therapy as sole therapy for advanced heart failure. Again, Jim did a good job emphasizing and placing this group of patients and the results of the study in the context of the fact that these are critically ill patients. All had class IV congestive heart failure for at least 90 days. All had an ejection fraction less than 25%. All had a VO₂ max less than 12 mL/kg/min, and most important all had no other therapy (ie, heart transplantation). The principle finding of the present study in this cohort of 23 patients undergoing DT in Utah is a 1-year survival of 77% versus 52% in . . . [Full Text of this Article]

Related Article

Improving outcomes with long-term "destination" therapy using left ventricular assist devices

James W. Long, Aaron H. Healy, Brad Y. Rasmusson, Cris G. Cowley, Karl E. Nelson, Abdallah G. Kfoury, Stephen E. Clayson, Bruce B. Reid, Stephanie A. Moore, Douglas U. Blank, and Dale G. Renlund
J. Thorac. Cardiovasc. Surg. 2008 135: 1353-1361. [Abstract] [Full Text] [PDF]